← Back to directory
TR
Third Rock Ventures
Boston, MassachusettsWebsite ↗
Third Rock Ventures is a venture capital firm dedicated to building companies that translate scientific innovations into breakthrough medicines, primarily within the life sciences sector. They aim to advance disruptive areas of science and medicine to deliver transformative products to patients.
Last raised
Jun 2022
4y ago
Latest fund size
$1.1B
Fund VI
AUM
$3.8B
estimated
Funds raised
Capital this firm has raised, newest first
Fund VI
Jun 2022 · Fund VI
$1.1B
Fund V
Jun 2019 · Fund V
$770M
Fund IV
Oct 2016 · Fund IV
$616M
Fund III
Jan 2013 · Fund III
$516M
Fund I
Jan 2007 · Fund I
—
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| Perpetual Medicines | — | — | Jun 2026 | |
| Terremoto Biosciences | — | — | Apr 2026 | |
| Syremis TherapeuticsLead | Series A | $165M | Dec 2025 | |
| Azalea Therapeutics | — | $82M | Oct 2025 | |
| Rapport Therapeutics | — | — | Jan 2025 | |
| Maze Therapeutics | — | — | Nov 2024 | |
| Trace NeuroscienceLead | — | $101M | Nov 2024 | |
| Seaport Therapeutics | Series B | — | Oct 2024 |
Sources
Where this data came from